The clinical trials program featuring our lead candidate, EXL01, is progressing at full speed, even in the summer.

Two partner-led oncology clinical trials, BIG and MOTHER, have recently received DSMB approval confirming once again the good safety and tolerance profile of our lead candidate.

These trials are evaluating the safety and efficacy of EXL01, our NOD2-targeting biotherapeutic designed to enhance the efficacy of immune checkpoint inhibitors.

- The BIG trial, powered by GERCOR, is using EXL01 in combination with nivolumab (anti-PD-L1) plus FOLFOX (chemotherapy) in first-line gastric cancer. EXL01 is designed to reprogram macrophages and enhance checkpoint inhibitor efficacy. Part two of the trial is due to start in September 2025

- MOTHER, a trial in hepatocellular carcinoma, is investigating the safety and efficacy of EXL01 in combination with immune checkpoint inhibitors, with the aim to boost their efficacy and convert previously non-responsive patients into responders. The trial is led by Professor Julien Edeline at Centre Eugène Marquis of Rennes.

More information on BIG (NCT0625361) and MOTHER (NCT06551272) can be found on https://lnkd.in/eJsJN5J